title: Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?
abstract: Multiparametric magnetic resonance imaging (mpMRI) is increasingly being used earlier in the prostate cancer diagnostic pathway in order to detect and localize disease. Its results can be used to help decide on the indication, type, and localization of a prostate biopsy for cancer diagnosis. In addition, mpMRI has the potential to contribute information on the characterization, or aggressiveness, of detected cancers including tumor progression over time. There is considerable variation in the way results of different MRI sequences are reported. We conducted a review of scoring systems that have been used in the detection and characterization of prostate cancer. This revealed that existing scoring and reporting systems differ in purpose, scale, and range. We evaluate these differences in this review. This first step in collating all methods of scoring and reporting mpMRI will ultimately lead to consensus approaches to develop a standardized reporting scheme that can be widely adopted and validated to ensure comparability of research outputs and optimal clinical practice.
authors.affiliation: Division of Surgery and Interventional Science, University College London, London, UK. ldickinson@doctors.org.uk
authors.forename: Louise
authors.initials: L
authors.lastname: Dickinson
authors.forename: Hashim U
authors.initials: HU
authors.lastname: Ahmed
authors.forename: Clare
authors.initials: C
authors.lastname: Allen
authors.forename: Jelle O
authors.initials: JO
authors.lastname: Barentsz
authors.forename: Brendan
authors.initials: B
authors.lastname: Carey
authors.forename: Jurgen J
authors.initials: JJ
authors.lastname: Futterer
authors.forename: Stijn W
authors.initials: SW
authors.lastname: Heijmink
authors.forename: Peter
authors.initials: P
authors.lastname: Hoskin
authors.forename: Alex P
authors.initials: AP
authors.lastname: Kirkham
authors.forename: Anwar R
authors.initials: AR
authors.lastname: Padhani
authors.forename: Raj
authors.initials: R
authors.lastname: Persad
authors.forename: Philippe
authors.initials: P
authors.lastname: Puech
authors.forename: Shonit
authors.initials: S
authors.lastname: Punwani
authors.forename: Aslam
authors.initials: A
authors.lastname: Sohaib
authors.forename: Bertrand
authors.initials: B
authors.lastname: Tombal
authors.forename: Arnauld
authors.initials: A
authors.lastname: Villers
authors.forename: Mark
authors.initials: M
authors.lastname: Emberton
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D015331:Cohort Studies; D003287:Contrast Media / Q000494:pharmacology; D003952:Diagnostic Imaging / Q000379:methods*; D018450:Disease Progression; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods* / Q000592:standards*; D008297:Male; D008495:Medical Oncology / Q000379:methods; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology* / Q000503:physiopathology; D011786:Quality Control; D012372:ROC Curve
chemical_list: D015415:Biomarkers; D003287:Contrast Media